Ownership
Private
Employees
~100
Therapeutic Areas
GastroenterologyHematologyRare DiseasesNeurology
Stage
Commercial
Modalities
Small moleculeSmall molecule

Marathon Pharmaceuticals General Information

Developed Emflaza (deflazacort) for Duchenne muscular dystrophy. Received FDA approval in February 2017. Sold rights to PTC Therapeutics for $140M after pricing controversy.

Contact Information

Website
Primary Industry
[ "Biotech", "Pharma" ]
Corporate Office
Northbrook, Illinois
United States

Drug Pipeline

deflazacort
Commercial
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Marathon Pharmaceuticals's pipeline data

Book a demo

Key Partnerships

PTC Therapeutics

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Marathon Pharmaceuticals Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Marathon Pharmaceuticals's complete valuation and funding history, request access »